October 09, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025
Go back

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in the field of migraine.

Additional eligibility requirements are listed below.

More Information

Application requirements 
AbbVie is looking for early-stage biotech companies that fit the following criteria: 

  • Have primary business location in US, France or Germany​
  • Be an early stage-startup focused on developing novel therapeutic approaches for migraine that could include both central and peripheral mechanisms for treating acute migraine and migraine prevention.​
  • Related research areas in pain with potential application(s) to migraine will also be considered.
  • Excluded are devices, neuromodulation technologies and similar technologies.
  • For additional requirements refer to the Terms and Conditions document.

Therapeutic focus of this call for applications: Migraine

Our latest News

discover more
AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in […]

read more
Two Life Sciences Bridge Awards for Heidelberg researchers

Two Life Sciences Bridge Awards for Heidelberg researchers

Double success for Heidelberg life sciences: Two of the three prestigious Life Sciences Bridge Awards presented this year go to Heidelberg University’s Medical Faculty. The Aventis Foundation honors infectious disease specialist Dr. Frauke Mücksch and neurologist Dr. Varun Venkataramani for their groundbreaking research. While Mücksch is searching for new ways to one day cure HIV […]

read more
How Fibrosis Disrupts the Heart’s Electrical Signals

How Fibrosis Disrupts the Heart’s Electrical Signals

Innovative imaging technique reveals hidden electrical connections in diseased hearts and provides new therapeutic approaches Cardiac fibrosis can be life-threatening: the formation of connective tissue in the heart muscle causes it to become stiffer, impairs electrical signal transmission, and weakens pumping capacity, which can lead to cardiac arrhythmias. However, the effects of cardiac fibrosis on […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp